Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Oxford handbook of practical drug therapy / / Duncan Richards [and three others]
| Oxford handbook of practical drug therapy / / Duncan Richards [and three others] |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | New York, [New York] : , : Oxford University Press, , 2011 |
| Descrizione fisica | 1 online resource (818 p.) |
| Disciplina | 615.1 |
| Collana | Oxford handbooks |
| Soggetto topico |
Drugs - Prescribing
Chemotherapy Pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-19-103388-X
0-19-172637-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Symbols and abbreviations; How to use this book; Introductory sections; Prescribing; The drug history; Writing a prescription; Generic drugs and biosimilars; Repeat prescriptions; 'Off-licence' drugs; Cautionary and advisory labels; Some basic concepts; The World Health Organization (WHO) essential medicines list; Compliance, adherence, and concordance; Guidelines; Dose-response curves (concentration-effect curves); Efficacy of drugs; Adverse drug reactions; Drug-drug interactions; Placebos; Changing the doses of drugs; Renal insufficiency; Hepatic insufficiency
An approach to rational prescribingPaediatric prescribing; Drugs and pregnancy; Drug therapy and breastfeeding; Drug development; 1 Gastrointestinal system; Gastric acid suppression; Histamine H[sub(2)] receptor antagonists: BNF 1.3.1; Proton pump inhibitors (PPIs): BNF 1.3.5; Misoprostol: BNF 1.3.4, 10.1.1; Drugs affecting gastrointestinal motility; Constipation: BNF 1.6; Co-phenotrope (Lomotil[sup(®)]): BNF 1.4.2; Loperamide (Imodium[sup(®)]): BNF 1.4.2; Inflammatory bowel disease; Mesalazine and related compounds (aminosalicylates): BNF 1.5; Sulfasalazine: BNF 1.5.1 and 10.1.3 Liver, biliary system, and lipidsCholic acids: BNF 1.9.1; HMG CoA reductase inhibitors ('statins'): BNF 2.12; Ezetimibe: BNF 2.12; Fibrates: BNF 2.12; Obesity; Orlistat: BNF 4.5.1; Antiemetics; Metoclopramide: BNF 4.6; Prochlorperazine (Stemetil[sup(®)]): BNF 4.6; Domperidone: BNF 4.6; Serotonin 5-HT[sub(3)] receptor antagonists: BNF 4.6; 2 Cardiovascular system; A pharmacological approach to the treatment of arrhythmias: BNF 2.3.1; Antiarrhythmic drugs; Adenosine: BNF 2.3.2; Flecainide BNF: 2.3.2; Cardiac glycosides (digitalis): BNF 2.1.1, 2.3.1, and 2.5.5; Disopyramide: BNF 2.3.2 Amiodarone: BNF 2.3.2 and 2.7.3Anticoagulants, antiplatelet drugs, and fibrinolytic drugs; Heparins (unfractionated and low molecular weight): BNF 2.8.1; Direct thrombin inhibitors: BNF 2.8.2; Fondaparinux sodium: BNF 2.8.1; Warfarin: BNF 2.8.2; Acetylsalicylic acid (aspirin): BNF 2.9 and 4.7.1; Clopidogrel: BNF 2.9; Dipyridamole: BNF 2.9; Glycoprotein IIb/IIIa antagonists: BNF 2.9; Fibrinolytic drugs: BNF 2.10.2 and 13.11.7; Ischaemic heart disease; Pharmacology of drugs used to treat acute coronary syndromes, including myocardial infarction: BNF 2.10 Pharmacology of drugs used to treat heart failureNitrate drugs: BNF 2.6.1; Nicorandil: BNF 2.6.3; Beta-adrenoceptor antagonists ('beta-blockers'): BNF 2.4, 2.5.5, 6.2.2, 4.7.4, 11.6; Angiotensin converting enzyme inhibitors (ACE inhibitors): BNF 2.5.5.1; Angiotensin receptor antagonists/blockers (ARBs): BNF 2.5.5.2; Hypertension; An approach to the treatment of hypertension: BNF 2.5; Methyldopa (alpha-methyldopa): BNF 2.5.2; Calcium channel blockers; Calcium channel blockers (see also individual sections): BNF 2.6.2; Dihydropyridines (nifedipine-like): BNF 2.6.2 Benzothiazepines (diltiazem): BNF 2.6.2 and 2.3.2 |
| Record Nr. | UNINA-9910464469103321 |
| New York, [New York] : , : Oxford University Press, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oxford handbook of practical drug therapy / / Duncan Richards [and three others]
| Oxford handbook of practical drug therapy / / Duncan Richards [and three others] |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | New York, [New York] : , : Oxford University Press, , 2011 |
| Descrizione fisica | 1 online resource (818 p.) |
| Disciplina | 615.1 |
| Collana | Oxford handbooks |
| Soggetto topico |
Drugs - Prescribing
Chemotherapy Pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-19-104367-2
0-19-103388-X 0-19-172637-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Symbols and abbreviations; How to use this book; Introductory sections; Prescribing; The drug history; Writing a prescription; Generic drugs and biosimilars; Repeat prescriptions; 'Off-licence' drugs; Cautionary and advisory labels; Some basic concepts; The World Health Organization (WHO) essential medicines list; Compliance, adherence, and concordance; Guidelines; Dose-response curves (concentration-effect curves); Efficacy of drugs; Adverse drug reactions; Drug-drug interactions; Placebos; Changing the doses of drugs; Renal insufficiency; Hepatic insufficiency
An approach to rational prescribingPaediatric prescribing; Drugs and pregnancy; Drug therapy and breastfeeding; Drug development; 1 Gastrointestinal system; Gastric acid suppression; Histamine H[sub(2)] receptor antagonists: BNF 1.3.1; Proton pump inhibitors (PPIs): BNF 1.3.5; Misoprostol: BNF 1.3.4, 10.1.1; Drugs affecting gastrointestinal motility; Constipation: BNF 1.6; Co-phenotrope (Lomotil[sup(®)]): BNF 1.4.2; Loperamide (Imodium[sup(®)]): BNF 1.4.2; Inflammatory bowel disease; Mesalazine and related compounds (aminosalicylates): BNF 1.5; Sulfasalazine: BNF 1.5.1 and 10.1.3 Liver, biliary system, and lipidsCholic acids: BNF 1.9.1; HMG CoA reductase inhibitors ('statins'): BNF 2.12; Ezetimibe: BNF 2.12; Fibrates: BNF 2.12; Obesity; Orlistat: BNF 4.5.1; Antiemetics; Metoclopramide: BNF 4.6; Prochlorperazine (Stemetil[sup(®)]): BNF 4.6; Domperidone: BNF 4.6; Serotonin 5-HT[sub(3)] receptor antagonists: BNF 4.6; 2 Cardiovascular system; A pharmacological approach to the treatment of arrhythmias: BNF 2.3.1; Antiarrhythmic drugs; Adenosine: BNF 2.3.2; Flecainide BNF: 2.3.2; Cardiac glycosides (digitalis): BNF 2.1.1, 2.3.1, and 2.5.5; Disopyramide: BNF 2.3.2 Amiodarone: BNF 2.3.2 and 2.7.3Anticoagulants, antiplatelet drugs, and fibrinolytic drugs; Heparins (unfractionated and low molecular weight): BNF 2.8.1; Direct thrombin inhibitors: BNF 2.8.2; Fondaparinux sodium: BNF 2.8.1; Warfarin: BNF 2.8.2; Acetylsalicylic acid (aspirin): BNF 2.9 and 4.7.1; Clopidogrel: BNF 2.9; Dipyridamole: BNF 2.9; Glycoprotein IIb/IIIa antagonists: BNF 2.9; Fibrinolytic drugs: BNF 2.10.2 and 13.11.7; Ischaemic heart disease; Pharmacology of drugs used to treat acute coronary syndromes, including myocardial infarction: BNF 2.10 Pharmacology of drugs used to treat heart failureNitrate drugs: BNF 2.6.1; Nicorandil: BNF 2.6.3; Beta-adrenoceptor antagonists ('beta-blockers'): BNF 2.4, 2.5.5, 6.2.2, 4.7.4, 11.6; Angiotensin converting enzyme inhibitors (ACE inhibitors): BNF 2.5.5.1; Angiotensin receptor antagonists/blockers (ARBs): BNF 2.5.5.2; Hypertension; An approach to the treatment of hypertension: BNF 2.5; Methyldopa (alpha-methyldopa): BNF 2.5.2; Calcium channel blockers; Calcium channel blockers (see also individual sections): BNF 2.6.2; Dihydropyridines (nifedipine-like): BNF 2.6.2 Benzothiazepines (diltiazem): BNF 2.6.2 and 2.3.2 |
| Record Nr. | UNINA-9910664101203321 |
| New York, [New York] : , : Oxford University Press, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||